NICE Recommends Takeda’s Entyvio, But Only At Discounted Price
This article was originally published in The Pink Sheet Daily
Executive Summary
An undisclosed price discount was key to U.K.’s National Institute for Health and Care Excellence recommending use of the gut-selective therapy vedolizumab in patients with moderate-to-severe ulcerative colitis in the National Health Service.